The short answer
Avoid self-starting an ephedrine-alkaloid-containing ephedra supplement while taking methamphetamine. Ephedra has serious cardiovascular risks, and a cautious review is especially important with a medicine that can raise blood pressure and pulse.
What this answer covers
Herba Ephedrae products containing ephedrine alkaloids; do not assume all species, plant parts or alkaloid-free products are equivalent.
- Supplement or preparation
- Herba Ephedrae
- Medication ingredient
- methamphetamine
Ephedra carries its own safety concern
NCCIH links ephedra to high blood pressure and other serious harm. U.S. dietary supplements containing ephedrine alkaloids are banned. This concern is present even without methamphetamine.
What the human studies measured
One small ephedra-and-caffeine study found increased systolic pressure and pulse. A different multi-ingredient study found no average pressure or QT change, although one participant had a large QT change. Neither isolated this methamphetamine pair.
A time gap does not establish safety
The evidence does not establish an interval that prevents combined stimulant effects. Tell the prescriber exactly which ephedra preparation you have used, including caffeine or other added ingredients.
Symptoms that need attention
Seek urgent medical care for chest pain, shortness of breath or fainting while taking methamphetamine. Tell your prescriber about new palpitations, troublesome stimulation or sleep disruption, and let the treating team decide on medication changes.
Evidence and practical considerations
Side effects & toxicity
A conditional cardiovascular precaution is supported by ephedra safety guidance and methamphetamine labeling, without a quantified exact-pair effect.
- Exact scope
- Herba Ephedrae products containing ephedrine alkaloids; do not assume all species, plant parts or alkaloid-free products are equivalent. with Prescribed oral S-methamphetamine hydrochloride; RxNorm 6816 IN and label section 11 establish active-moiety relationship, not dose or stereoisomer interchangeability.
- Medication form and route
- oral
- Timing or duration
- Dose, pattern of use and preparation matter; no universal protective spacing interval established.
What remains uncertain
- Clinical trials used ephedra plus caffeine or larger mixtures, not methamphetamine; exact combined hypertension risk remains unmeasured.
Factors that may matter: exact product; other medicines; prescribed dose; baseline cardiovascular or serotonergic risk.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral methamphetamine hydrochloride tablets.
Sections 2.4 and 7.1 identify acidifying agents such as ascorbic acid as lowering levels and alkalinizing agents such as sodium bicarbonate as increasing levels; avoid gastrointestinal and urinary alkalinizing co-use. Sections 5.8 and 7.1 warn about serotonin syndrome with serotonergic agents, specifically including tryptophan and St Johns wort. Section 5.3 calls for blood-pressure and pulse monitoring.
How this applies: RxNorm 6816 IN maps to this SPL, and description confirms active ingredient salt relationship. Applies to prescribed oral S-methamphetamine hydrochloride, not other stimulants or unapproved routes.
Regulatory guidance is not a quantified trial for every named pair. No one-hour supplement spacing instruction. General amphetamine language is explicitly incorporated in this exact methamphetamine product label.
Source 2: official safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of ephedra alkaloid-containing products.
Linked to serious harm including hypertension; FDA banned dietary supplements containing ephedrine alkaloids. Interaction with other stimulants is described as theoretical.
How this applies: Supports avoiding alkaloid-containing supplement self-use and reviewing exposure.
Intrinsic ephedra harm is not direct evidence of additive methamphetamine toxicity; composition matters.
Source 3: original clinical study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eight healthy adults.
Systolic pressure and heart rate increased; diastolic pressure did not significantly change.
How this applies: Supports only the specific result and preparation described; applicability to prescribed oral methamphetamine is explicitly limited.
Contains caffeine, so ephedra-only effects cannot be isolated. No methamphetamine or long-term safety estimate.
Source 4: original clinical study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 13 healthy volunteers.
No group difference in QTc or systolic blood pressure; one participant had a large QTc increase requiring further study.
How this applies: Supports only the specific result and preparation described; applicability to prescribed oral methamphetamine is explicitly limited.
Small mixture study, no methamphetamine. Neither a universal QT warning nor a safety assurance is justified.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current available claims adjudicated from inspected sources; no clinical review asserted. | |
| Research summary published |
Article revision: 14f9f95fe22f4568
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.